Zobrazeno 1 - 7
of 7
pro vyhledávání: '"David J. Zelinger"'
Publikováno v:
American Heart Journal, 135(4), 98-106. Mosby Inc.
Cost-effectiveness analyses are routinely performed to determine whether the additional cost of a novel therapy is balanced by additional effectiveness. The definitions of costs and effects involve a variety of assumptions, both in general economic t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd77d0756a08d2cfc292429dd81017da
https://doi.org/10.1016/s0002-8703(98)70302-3
https://doi.org/10.1016/s0002-8703(98)70302-3
Publikováno v:
Regulatory Toxicology and Pharmacology. 18:206-213
A retrospective evaluation of previously conducted acute tolerance tests in rats and mice, following oral and intravenous routes of administration, and a review of the literature indicated that a minimum of three animals per group was adequate to cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05b167caf28a4d40d8c5c69e1af6f32f
https://doi.org/10.1006/rtph.1993.1054
https://doi.org/10.1006/rtph.1993.1054
Publikováno v:
Toxicological Sciences. 20:147-154
Ipazilide fumarate (WIN 54177-4) is a chemically novel antiarrhythmic agent that prolongs ventricular refractoriness and possesses antiectopic activity. The compound is being developed as oral and iv therapy for ventricular and supraventricular arrhy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ddbd5e4b11dbdb84dc4e8b3dc2d05c7
https://doi.org/10.1093/toxsci/20.2.147
https://doi.org/10.1093/toxsci/20.2.147
Autor:
Arnold E. Postlethwaite, Michael H. Weisman, Maureen D. Mayes, James N. Woody, William J. Koopman, David J. Zelinger, Larry W. Moreland, Robert W. Lightfoot, Thomas J. Schnitzer, Leonard Calabrese, Parks W. Pratt
Publikováno v:
Arthritis and rheumatism. 38(11)
Objective. To evaluate the clinical response to and safety of single and repeat doses of a chimeric anti-CD4 monoclonal antibody, cM-T412, in patients with rheumatoid arthritis (RA) concomitantly treated with a stable regimen of low-dose methotrexate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff0c63513c103bd961ccd3c3efba2a7
https://pubmed.ncbi.nlm.nih.gov/7488278
https://pubmed.ncbi.nlm.nih.gov/7488278
Autor:
David J. Zelinger, Robert H. Diamond, Steven T. Pals, Michael O. Montgomery, Marit M. van Santen
Publikováno v:
Gastroenterology. 140:S-737
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::937343d4b0da9b0e7e206b281f0cf443
https://doi.org/10.1016/s0016-5085(11)63068-0
https://doi.org/10.1016/s0016-5085(11)63068-0
Publikováno v:
Toxicologic pathology. 21(1)
Recombinant human interleukin 4 (rhuIL-4) is a candidate for the treatment of refractory cancer based on its potential to enhance immune function. Recombinant human IL-4 was administered subcutaneously at 0, 1, 5, or 25 μg/kg/day for 28 days with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d112e09c9c412e6c00b02750a8c41942
https://pubmed.ncbi.nlm.nih.gov/8378706
https://pubmed.ncbi.nlm.nih.gov/8378706
Autor:
Robert L. Dixon, Thomas A. Barbolt, David J. Zelinger, Yigal Greener, David P. Benziger, Jon P. Kimball, Brian A. Mayes, Alan M. Ezrin, Raymond M. Everett, Jack H. Dean
Publikováno v:
Fundamental and applied toxicology : official journal of the Society of Toxicology. 18(4)
Ipazilide fumarate (Win 54,177-4) is a chemically novel antiarrhythmic agent that prolongs ventricular refractoriness and possesses antiectopic activity. Subchronic (29 days) nonclinical safety evaluation of ipazilide was conducted following oral and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb15ff38bad2cad531432310bf7055a
https://pubmed.ncbi.nlm.nih.gov/1526370
https://pubmed.ncbi.nlm.nih.gov/1526370